International lung cancer consortium

Pooled analysis of sequence variants in DNA repair and cell cycle pathways

Rayjean J. Hung, David C. Christiani, Angela Risch, Odilia Popanda, Aage Haugen, Shan Zienolddiny, Simone Benhamou, Christine Bouchardy, Qing Lan, Margaret R. Spitz, H. Erich Wichmann, Loic LeMarchand, Paolo Vineis, Giuseppe Matullo, Chikako Kiyohara, Zuo Feng Zhang, Benhnaz Pezeshki, Curtis Harris, Leah Mechanic, Adeline Seow & 33 others Daniel P K Ng, Neonila Szeszenia-Dabrowska, David Zaridze, Jolanta Lissowska, Peter Rudnai, Eleonora Fabianova, Dana Mates, Lenka Foretova, Vladimir Janout, Vladimir Bencko, Neil Caporaso, Chu Chen, Eric J. Duell, Gary Goodman, John K. Field, Richard S. Houlston, Yun Chul Hong, Maria Teresa Landi, Philip Lazarus, Joshua Muscat, John McLaughlin, Ann G. Schwartz, Hongbing Shen, Isabelle Stucker, Kazuo Tajima, Keitaro Matsuo, Michael Thun, Ping Yang, John Wiencke, Angeline S. Andrew, Stephanie Monnier, Paolo Boffetta, Paul Brennan

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Background: The International Lung Cancer Consortium was established in 2004. To clarify the role of DNA repair genes in lung cancer susceptibility, we conducted a pooled analysis of genetic variants in DNA repair pathways, whose associations have been investigated by at least 3 individual studies. Methods: Data from 14 studies were pooled for 18 sequence variants in 12 DNA repair genes, including APEX1, OGG1, XRCC1, XRCC2, XRCC3, ERCC1, XPD, XPF, XPG, XPA, MGMT, and TP53. The total number of subjects included in the analysis for each variant ranged from 2,073 to 13,955 subjects. Results: Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95% confidence interval (95% CI), 0.79-0.99 and homozygote OR, 0.84; 95% CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95% CI, 0.89-1.10 and homozygote OR, 1.19; 95% CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95% CI, 1.00-1.29 and homozygote OR, 1.20; 95% CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies. OGG1 S326C homozygote was suggested to be associated with lung cancer risk in Caucasians (homozygote OR, 1.34; 95% CI, 1.01-1.79) based on 2,569 cases and 4,178 controls from 4 studies but not in Asians. The other 14 variants did not exhibit main effects on lung cancer risk. Discussion: In addition to data pooling, future priorities of International Lung Cancer Consortium include coordinated genotyping and multistage validation for ongoing genome-wide association studies.

Original languageEnglish (US)
Pages (from-to)3081-3089
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number11
DOIs
StatePublished - Nov 2008

Fingerprint

DNA Repair
Sequence Analysis
Lung Neoplasms
Cell Cycle
Homozygote
Odds Ratio
Confidence Intervals
Heterozygote
Genome-Wide Association Study
Genes
Meta-Analysis

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

International lung cancer consortium : Pooled analysis of sequence variants in DNA repair and cell cycle pathways. / Hung, Rayjean J.; Christiani, David C.; Risch, Angela; Popanda, Odilia; Haugen, Aage; Zienolddiny, Shan; Benhamou, Simone; Bouchardy, Christine; Lan, Qing; Spitz, Margaret R.; Wichmann, H. Erich; LeMarchand, Loic; Vineis, Paolo; Matullo, Giuseppe; Kiyohara, Chikako; Zhang, Zuo Feng; Pezeshki, Benhnaz; Harris, Curtis; Mechanic, Leah; Seow, Adeline; Ng, Daniel P K; Szeszenia-Dabrowska, Neonila; Zaridze, David; Lissowska, Jolanta; Rudnai, Peter; Fabianova, Eleonora; Mates, Dana; Foretova, Lenka; Janout, Vladimir; Bencko, Vladimir; Caporaso, Neil; Chen, Chu; Duell, Eric J.; Goodman, Gary; Field, John K.; Houlston, Richard S.; Hong, Yun Chul; Landi, Maria Teresa; Lazarus, Philip; Muscat, Joshua; McLaughlin, John; Schwartz, Ann G.; Shen, Hongbing; Stucker, Isabelle; Tajima, Kazuo; Matsuo, Keitaro; Thun, Michael; Yang, Ping; Wiencke, John; Andrew, Angeline S.; Monnier, Stephanie; Boffetta, Paolo; Brennan, Paul.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 17, No. 11, 11.2008, p. 3081-3089.

Research output: Contribution to journalArticle

Hung, RJ, Christiani, DC, Risch, A, Popanda, O, Haugen, A, Zienolddiny, S, Benhamou, S, Bouchardy, C, Lan, Q, Spitz, MR, Wichmann, HE, LeMarchand, L, Vineis, P, Matullo, G, Kiyohara, C, Zhang, ZF, Pezeshki, B, Harris, C, Mechanic, L, Seow, A, Ng, DPK, Szeszenia-Dabrowska, N, Zaridze, D, Lissowska, J, Rudnai, P, Fabianova, E, Mates, D, Foretova, L, Janout, V, Bencko, V, Caporaso, N, Chen, C, Duell, EJ, Goodman, G, Field, JK, Houlston, RS, Hong, YC, Landi, MT, Lazarus, P, Muscat, J, McLaughlin, J, Schwartz, AG, Shen, H, Stucker, I, Tajima, K, Matsuo, K, Thun, M, Yang, P, Wiencke, J, Andrew, AS, Monnier, S, Boffetta, P & Brennan, P 2008, 'International lung cancer consortium: Pooled analysis of sequence variants in DNA repair and cell cycle pathways', Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 11, pp. 3081-3089. https://doi.org/10.1158/1055-9965.EPI-08-0411
Hung, Rayjean J. ; Christiani, David C. ; Risch, Angela ; Popanda, Odilia ; Haugen, Aage ; Zienolddiny, Shan ; Benhamou, Simone ; Bouchardy, Christine ; Lan, Qing ; Spitz, Margaret R. ; Wichmann, H. Erich ; LeMarchand, Loic ; Vineis, Paolo ; Matullo, Giuseppe ; Kiyohara, Chikako ; Zhang, Zuo Feng ; Pezeshki, Benhnaz ; Harris, Curtis ; Mechanic, Leah ; Seow, Adeline ; Ng, Daniel P K ; Szeszenia-Dabrowska, Neonila ; Zaridze, David ; Lissowska, Jolanta ; Rudnai, Peter ; Fabianova, Eleonora ; Mates, Dana ; Foretova, Lenka ; Janout, Vladimir ; Bencko, Vladimir ; Caporaso, Neil ; Chen, Chu ; Duell, Eric J. ; Goodman, Gary ; Field, John K. ; Houlston, Richard S. ; Hong, Yun Chul ; Landi, Maria Teresa ; Lazarus, Philip ; Muscat, Joshua ; McLaughlin, John ; Schwartz, Ann G. ; Shen, Hongbing ; Stucker, Isabelle ; Tajima, Kazuo ; Matsuo, Keitaro ; Thun, Michael ; Yang, Ping ; Wiencke, John ; Andrew, Angeline S. ; Monnier, Stephanie ; Boffetta, Paolo ; Brennan, Paul. / International lung cancer consortium : Pooled analysis of sequence variants in DNA repair and cell cycle pathways. In: Cancer Epidemiology Biomarkers and Prevention. 2008 ; Vol. 17, No. 11. pp. 3081-3089.
@article{4b3be34c4c7b4e56b9b93c2763e35d67,
title = "International lung cancer consortium: Pooled analysis of sequence variants in DNA repair and cell cycle pathways",
abstract = "Background: The International Lung Cancer Consortium was established in 2004. To clarify the role of DNA repair genes in lung cancer susceptibility, we conducted a pooled analysis of genetic variants in DNA repair pathways, whose associations have been investigated by at least 3 individual studies. Methods: Data from 14 studies were pooled for 18 sequence variants in 12 DNA repair genes, including APEX1, OGG1, XRCC1, XRCC2, XRCC3, ERCC1, XPD, XPF, XPG, XPA, MGMT, and TP53. The total number of subjects included in the analysis for each variant ranged from 2,073 to 13,955 subjects. Results: Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95{\%} confidence interval (95{\%} CI), 0.79-0.99 and homozygote OR, 0.84; 95{\%} CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95{\%} CI, 0.89-1.10 and homozygote OR, 1.19; 95{\%} CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95{\%} CI, 1.00-1.29 and homozygote OR, 1.20; 95{\%} CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies. OGG1 S326C homozygote was suggested to be associated with lung cancer risk in Caucasians (homozygote OR, 1.34; 95{\%} CI, 1.01-1.79) based on 2,569 cases and 4,178 controls from 4 studies but not in Asians. The other 14 variants did not exhibit main effects on lung cancer risk. Discussion: In addition to data pooling, future priorities of International Lung Cancer Consortium include coordinated genotyping and multistage validation for ongoing genome-wide association studies.",
author = "Hung, {Rayjean J.} and Christiani, {David C.} and Angela Risch and Odilia Popanda and Aage Haugen and Shan Zienolddiny and Simone Benhamou and Christine Bouchardy and Qing Lan and Spitz, {Margaret R.} and Wichmann, {H. Erich} and Loic LeMarchand and Paolo Vineis and Giuseppe Matullo and Chikako Kiyohara and Zhang, {Zuo Feng} and Benhnaz Pezeshki and Curtis Harris and Leah Mechanic and Adeline Seow and Ng, {Daniel P K} and Neonila Szeszenia-Dabrowska and David Zaridze and Jolanta Lissowska and Peter Rudnai and Eleonora Fabianova and Dana Mates and Lenka Foretova and Vladimir Janout and Vladimir Bencko and Neil Caporaso and Chu Chen and Duell, {Eric J.} and Gary Goodman and Field, {John K.} and Houlston, {Richard S.} and Hong, {Yun Chul} and Landi, {Maria Teresa} and Philip Lazarus and Joshua Muscat and John McLaughlin and Schwartz, {Ann G.} and Hongbing Shen and Isabelle Stucker and Kazuo Tajima and Keitaro Matsuo and Michael Thun and Ping Yang and John Wiencke and Andrew, {Angeline S.} and Stephanie Monnier and Paolo Boffetta and Paul Brennan",
year = "2008",
month = "11",
doi = "10.1158/1055-9965.EPI-08-0411",
language = "English (US)",
volume = "17",
pages = "3081--3089",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - International lung cancer consortium

T2 - Pooled analysis of sequence variants in DNA repair and cell cycle pathways

AU - Hung, Rayjean J.

AU - Christiani, David C.

AU - Risch, Angela

AU - Popanda, Odilia

AU - Haugen, Aage

AU - Zienolddiny, Shan

AU - Benhamou, Simone

AU - Bouchardy, Christine

AU - Lan, Qing

AU - Spitz, Margaret R.

AU - Wichmann, H. Erich

AU - LeMarchand, Loic

AU - Vineis, Paolo

AU - Matullo, Giuseppe

AU - Kiyohara, Chikako

AU - Zhang, Zuo Feng

AU - Pezeshki, Benhnaz

AU - Harris, Curtis

AU - Mechanic, Leah

AU - Seow, Adeline

AU - Ng, Daniel P K

AU - Szeszenia-Dabrowska, Neonila

AU - Zaridze, David

AU - Lissowska, Jolanta

AU - Rudnai, Peter

AU - Fabianova, Eleonora

AU - Mates, Dana

AU - Foretova, Lenka

AU - Janout, Vladimir

AU - Bencko, Vladimir

AU - Caporaso, Neil

AU - Chen, Chu

AU - Duell, Eric J.

AU - Goodman, Gary

AU - Field, John K.

AU - Houlston, Richard S.

AU - Hong, Yun Chul

AU - Landi, Maria Teresa

AU - Lazarus, Philip

AU - Muscat, Joshua

AU - McLaughlin, John

AU - Schwartz, Ann G.

AU - Shen, Hongbing

AU - Stucker, Isabelle

AU - Tajima, Kazuo

AU - Matsuo, Keitaro

AU - Thun, Michael

AU - Yang, Ping

AU - Wiencke, John

AU - Andrew, Angeline S.

AU - Monnier, Stephanie

AU - Boffetta, Paolo

AU - Brennan, Paul

PY - 2008/11

Y1 - 2008/11

N2 - Background: The International Lung Cancer Consortium was established in 2004. To clarify the role of DNA repair genes in lung cancer susceptibility, we conducted a pooled analysis of genetic variants in DNA repair pathways, whose associations have been investigated by at least 3 individual studies. Methods: Data from 14 studies were pooled for 18 sequence variants in 12 DNA repair genes, including APEX1, OGG1, XRCC1, XRCC2, XRCC3, ERCC1, XPD, XPF, XPG, XPA, MGMT, and TP53. The total number of subjects included in the analysis for each variant ranged from 2,073 to 13,955 subjects. Results: Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95% confidence interval (95% CI), 0.79-0.99 and homozygote OR, 0.84; 95% CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95% CI, 0.89-1.10 and homozygote OR, 1.19; 95% CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95% CI, 1.00-1.29 and homozygote OR, 1.20; 95% CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies. OGG1 S326C homozygote was suggested to be associated with lung cancer risk in Caucasians (homozygote OR, 1.34; 95% CI, 1.01-1.79) based on 2,569 cases and 4,178 controls from 4 studies but not in Asians. The other 14 variants did not exhibit main effects on lung cancer risk. Discussion: In addition to data pooling, future priorities of International Lung Cancer Consortium include coordinated genotyping and multistage validation for ongoing genome-wide association studies.

AB - Background: The International Lung Cancer Consortium was established in 2004. To clarify the role of DNA repair genes in lung cancer susceptibility, we conducted a pooled analysis of genetic variants in DNA repair pathways, whose associations have been investigated by at least 3 individual studies. Methods: Data from 14 studies were pooled for 18 sequence variants in 12 DNA repair genes, including APEX1, OGG1, XRCC1, XRCC2, XRCC3, ERCC1, XPD, XPF, XPG, XPA, MGMT, and TP53. The total number of subjects included in the analysis for each variant ranged from 2,073 to 13,955 subjects. Results: Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95% confidence interval (95% CI), 0.79-0.99 and homozygote OR, 0.84; 95% CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95% CI, 0.89-1.10 and homozygote OR, 1.19; 95% CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95% CI, 1.00-1.29 and homozygote OR, 1.20; 95% CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies. OGG1 S326C homozygote was suggested to be associated with lung cancer risk in Caucasians (homozygote OR, 1.34; 95% CI, 1.01-1.79) based on 2,569 cases and 4,178 controls from 4 studies but not in Asians. The other 14 variants did not exhibit main effects on lung cancer risk. Discussion: In addition to data pooling, future priorities of International Lung Cancer Consortium include coordinated genotyping and multistage validation for ongoing genome-wide association studies.

UR - http://www.scopus.com/inward/record.url?scp=55849112266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55849112266&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-0411

DO - 10.1158/1055-9965.EPI-08-0411

M3 - Article

VL - 17

SP - 3081

EP - 3089

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -